Merck’s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection - BioSpace

Merck’s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection  BioSpace

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026 - Business Wire

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026  Business Wire

Daiichi Sankyo bags an industry first with Japanese nod for blood cancer drug Ezharmia - Fierce P...

Daiichi Sankyo bags an industry first with Japanese nod for blood cancer drug Ezharmia  Fierce Pharma

Daiichi Sankyo’s FLT3 Inhibitor Gets FDA Nod as First-Line AML Treatment - BioSpace

Daiichi Sankyo’s FLT3 Inhibitor Gets FDA Nod as First-Line AML Treatment  BioSpace

Paving the way for Merck's buyout, Seagen loses arbitration dispute with Daiichi Sankyo over ADC ...

Paving the way for Merck's buyout, Seagen loses arbitration dispute with Daiichi Sankyo over ADC tech  Endpoints News

Daiichi Sankyo Drops $1B to Boost ADC Manufacturing Capacity at German Site - BioSpace

Daiichi Sankyo Drops $1B to Boost ADC Manufacturing Capacity at German Site  BioSpace

USPTO Rules Against Seagen in ADC Patent Battle with Daiichi Sankyo - BioSpace

USPTO Rules Against Seagen in ADC Patent Battle with Daiichi Sankyo  BioSpace